Literature DB >> 11958379

What is an oligodendroglioma?

Peter C Burger1.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11958379     DOI： 10.1111/j.1750-3639.2002.tb00440.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN： 1015-6305            Impact factor:   6.508


× No keyword cloud information.
  27 in total

1.  Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Authors:  Katherine S Panageas; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M Deangelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2012-05-31       Impact factor: 12.300

2.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

Review 3.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

4.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

5.  Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma.

Authors:  Xianzhen Chen; Weidong Zang; Fei Xue; Zhaoli Shen; Quanbin Zhang
Journal:  Neurol Sci       Date:  2012-09-30       Impact factor: 3.307

Review 6.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

Review 7.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

8.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 9.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.

Authors:  Martin J van den Bent
Journal:  Acta Neuropathol       Date:  2010-07-20       Impact factor: 17.088

10.  Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Authors:  Katherine S Panageas; Anne S Reiner; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2014-07-04       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.